Efficiently Creating Value with Innovative Science


NASDAQ: OXGN

$ 2.49 0.11 (4.62%)
Day High: 2.56
Day Low:  2.39
Volume:    644,600
4:00 PM ET
Jul 23, 2014

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
Date Title and Summary View
Jul 23, 2014 SOUTH SAN FRANCISCO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second quarter 2014 results on Tuesday, August 5, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 p.m. ET (1:30 p.m. PT)...
May 23, 2014 SOUTH SAN FRANCISCO, Calif., May 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $16 million of registered shares of OXiGENE common stock in an at-the-mar...
May 16, 2014 SOUTH SAN FRANCISCO, Calif., May 16, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appointed to the position of President and Chief Executive Officer, replacing Peter Langecker, M.D., Ph.D. Dr...
May 6, 2014 Company Strengthens Cash Position by $20 Million Announced Positive Phase 2 Data in Recurrent Ovarian Cancer for ZYBRESTAT® in Combination With Avastin® SOUTH SAN FRANCISCO, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to trea...
Apr 22, 2014 SOUTH SAN FRANCISCO, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first quarter 2014 results on Tuesday May 6, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT). ...
Apr 7, 2014 SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Me...
Mar 27, 2014 SOUTH SAN FRANCISCO, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Canc...
Mar 18, 2014 SOUTH SAN FRANCISCO, Calif., March 18, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013. Commented Peter Langecker, M.D., Ph.D., OXiGENE's Chief Executive Officer: "During the past ye...
Mar 11, 2014 SOUTH SAN FRANCISCO, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin® (bevacizumab) with or without ZYBRESTAT® (fosbretabulin; CA4P) ...
Mar 11, 2014 SOUTH SAN FRANCISCO, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company's presentation and webcast at the ROTH Capital Partners 26th Annual Growth Stock Conference will take place on Wednesday, March 12 at 9:30 a...
Page:
1
... NextLast
= add release to Briefcase